Managing erythropoietin hyporesponsiveness

Seminars in Dialysis

Volumn 19, Issue 2, 2006, Pages 146-151

  Kwack, Christina ^a   Balakrishnan, Vaidyanathapuram S ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; CARNITINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD; CHRONIC KIDNEY FAILURE; HUMAN; HYPERPARATHYROIDISM; INFLAMMATION; OXIDATIVE STRESS; RENAL REPLACEMENT THERAPY; REVIEW; VITAMIN DEFICIENCY;

ALUMINUM; ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AVITAMINOSIS; CARNITINE; ERYTHROPOIETIN, RECOMBINANT; HUMANS; HYPERPARATHYROIDISM; INFLAMMATION; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; RENAL DIALYSIS;

EID: 33645292037     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00141.x     Document Type: Review

References (45)

1. Astor B Muntner P Levin A Gustace J Coresh J Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 162 1401 1408 2002
2. Hsu C-Y Bates D Kuperman G Curhan G Relationship between hematocrit and renal function in men and women. Kidney Int 59 725 731 2001
3. Hsu C-Y McCulloch C Curhan G Epidemiology of anemia associated with chronic renal insufficiency among adults in the US: results from the Third National Health and Nutrition Survey. J Am Soc Nephrol 13 504 510 2002
4. Collins A Ebben J Ma J Manning W Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 36 282 293 2000
5. Kausz A Solid C Pereira B Collins A St. Peter W Intractable anemia among HD patients: a sign of suboptimal management or a marker of disease. Am J Kidney Dis 45 136 147 2005
6. Canadian Erythropoietin Study Group Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 300 573 578 1990
7. Foley R Parfrey P Morgan J Barre P Campbell P Cartier P Coyle D Fine A Handa P Kingma I Lau C Levin A Mendelssohn D Muirhead N Murphy B Plante R Posen G Wells G Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58 1325 1335 2000
8. Roger S McMahon L Clarkson A Disney A Harris D Hawley C Healy H Kerr P Lynn K Parnhem A Pascue R Voss D Walker R Levin A Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 15 148 156 2004
9. Drueke T Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16 25 28 2001
10. Besarab A Amin N Ahsan M Vogel S Zazuwa G Frinak S Zazraj J Anandan J Gupta A Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11 530 538 2000
11. Fishbane S Shapiro W Dutka P Valenzuela O Faubert J A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60 2406 2411 2001
12. Kaufman J Reda D Fye C Goldfarb D Henderson W Kleinman J Vaamonde CA Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients Diagnostic value of iron indices in hemodialysis patients receiving epoetin. Kidney Int 60 300 308 2001
13. Lin J Chang M Tan D Leu M Short-term small dose intravenous iron trial to detect functional iron deficiency in dialysis patients. Am J Nephrol 21 91 97 2001
14. Tessitore N Sdero G Lippi G Bassi A Faccini G Bedogna V Gammaro L Brocco G Restivo G Bernich P Lupo A Maschio G The role of iron status markers in predicting response to intravenous iron in hemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16 1416 1423 2001
15. Aronoff G Safety of intravenous iron in clinical practice: implication for anemia management protocols. J Am Soc Nephrol 15 S99 S106 2004
16. DeVita M Framkin D Mittal S Kamran A Fishbane S Michelis M Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 60 335 340 2003
17. Fishbane S Galgano C Langley R Canfield W Maesaka J Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 52 217 222 1997
18. Macdougall I Tucker B Thompson J Tomson C Baker L Raine A A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50 1694 1699 1996
19. Fishbane S Kowalski E Imbriano L Maesaka J The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7 2654 2657 1996
20. Hoen B Paul-Dauphin A Hestin D Kessler M EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9 869 876 1998
21. Aronoff G Bennett W Blumenthal S Charytan C Pennell J Reed J Rothstein M Strom J Wolfe A Van Wyck D Yee J Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 66 1193 1198 2004
22. Besarab A Bolton W Browne J Egrie J Nissenson A Okamoto D Schwab S Goodkin D The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 584 590 1998
23. Feldman H Santanna J Guo W Furst H Franklin E Joffe M Marcus S Faich G Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13 734 744 2002
24. Kimmel P Phillips T Simmens S Peterson R Weihs K Alleyne S Cruz I Yanovski J Veis J Immunologic function and survival in hemodialysis patients. Kidney Int 54 236 244 1998
25. Sirken G Kung S Raja R Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J 49 422 425 2003
26. Cooper A Mikhail A Lethbridge M Kemeny D Macdougall I Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 15 1877 1882 2004
27. Himmelfarb J Stenvinkel P Ikizler T Hakim R The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62 1524 1538 2002
28. Roob J Khoschorur G Tiran A Horina J Holzer H Winklhofer-Roob B Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11 539 549 2000
29. Kato A Odamaki M Hishida A Blood 8-hydroxy-2′-deoxyguanosine is associated with erythropoietin resistance in hemodialysis patients. Nephrol Dial Transplant 18 931 936 2003
30. Cristol J Bosc J Badiou S Leblanc M Lorrho R Descomps B Canaud B Erythropoietin and oxidative stress in hemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 12 2312 2317 1997
31. McClellan W Frankenfield D Johnson C Owen W Rocco M Wish J Hematocrit and erythropoietin dose are associated with dose of dialysis among adult hemodialysis patients: results from the 1998 ESRD Core Indicators Project. J Am Soc Nephrol 11 287A 2000
32. Ifudu O Feldman J Friedman E The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 334 420 425 1996
33. Locatelli F Andrulli S Pecchini F Pedrini L Agliata S Lucchi L Farina M La Milia V Grassi C Borghi M Redaelli B Con te F Ratto G Cabiddu G Grossi C Modenese R Effect of high-flux dialysis on the anemia of hemodialysis patients. Nephrol Dial Transplant 15 1399 1409 2000
34. Richardson D Lindley E Bartlett C Will E A randomized controlled study of the consequences of hemodialysis membrane composition on erythropoietic response. Am J Kidney Dis 42 551 560 2003
35. Opatrny K Reischig T Vienken J Eiselt J Vit L Opatrna S Sefrna F Racek J Brown G Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis. Artif Organs 26 181 188 2002
36. Falko J Guy J Smith R Mazzaferri E Primary hyperparathyroidism and anemia. Arch Intern Med 136 887 889 1976
37. Mandolfo S Malberti F Farina M Villa G Scanziani R Surian M Imbasciati E Parathyroidectomy and response to erythropoietin therapy in anaemic patients with chronic renal failure. Nephrol Dial Transplant 13 2708 2709 1998
38. Labonia W L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 26 757 764 1995
39. Kletzmayr J Mayer G Legenstein E Heinz-Peer G Leitha T Horl W Kovarik J Anemia and carnitine supplementation in hemodialyzed patients. Kidney Int 69 S93 S106 1999
40. Hurot J Cucherat M Haugh M Fouque D Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 13 708 714 2002
41. Taji Y Morimoto T Okada K Fukuhara S Fukui T Kuwahara T Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients. J Nephrol 17 537 543 2004
42. Keven K Kutlay S Nergizoglu G Erturk S Randomized crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 41 1233 1239 2003
43. Albitar S Genin R Fen-Chong M Serveaux M Bourgeon B High dose enalapril impairs the response to erythropoietin treatment in hemodialysis patients. Nephrol Dial Transplant 13 1206 1210 1998
44. Azizi M Rousseau A Ezan E Guyene T Michelet S Grognet J Lenfant M Corvol P Menard J Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 97 839 844 1996
45. Casadevall N Cellular mechanism of resistance to erythropoietin. Nephrol Dial Transplant 10 27 30 1995